ReviewGastroenterology2014
From stool transplants to next-generation microbiota therapeutics.
Review in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Extracellular vesicles derived from Lactobacillus johnsonii promote gut barrier homeostasis by enhancing M2 macrophage polarization.Journal of advanced research · 2025Article
- Exploring the relationship betweenComputational and structural biotechnology journal · 2024Review
- Microfluidic Gastrointestinal Cell Culture Technologies-Improvements in the Past Decade.Biosensors · 2024Review
- The Microbiome Matters: Its Impact on Cancer Development and Therapeutic Responses.Journal of microbiology (Seoul, Korea) · 2024Review
- Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond.SAGE open medicine · 2024Review
- The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies.Current pharmaceutical biotechnology · 2024Review
- Biofilm's Impact on Inflammatory Bowel Diseases.Cureus · 2023Review
- Development of Gut Microbiota in the First 1000 Days after Birth and Potential Interventions.Nutrients · 2023Review
- Novel paradigms for the gut-brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder.Frontiers in psychiatry · 2023Article
- Target-enriched long-read sequencing (TELSeq) contextualizes antimicrobial resistance genes in metagenomes.Microbiome · 2022Article
- Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases.Antibiotics (Basel, Switzerland) · 2022Review
- Feeding Our Microbiota: Stimulation of the Immune/Semiochemical System and the Potential Amelioration of Non-Communicable Diseases.Life (Basel, Switzerland) · 2022Review
- Pilot study of autologous fecal microbiota transplants in nursing home residents: Feasibility and safety.Contemporary clinical trials communications · 2022Article
- Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine?Life (Basel, Switzerland) · 2022Review
- Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection.Cureus · 2022Article
- Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis.Gastro hep advances · 2022Article
- Microbiome therapeutics: exploring the present scenario and challenges.Gastroenterology report · 2022Review
- The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study.JMIR research protocols · 2021Article
- The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease.Journal of clinical medicine · 2021Review
- We and herbivores eat endophytes.Microbial biotechnology · 2021Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The epidemic of Clostridium difficile infection fueled by new virulent strains of the organism has led to increased use of fecal microbiota transplantation (FMT). The procedure is effective for even the most desperate cases after failure of multiple courses of antibiotics. The approach recognizes microbiota to be integral to normal human physiology, and microbiota being used in FMT represents a new class of therapeutics. Imbalance in the composition and altered activity of the microbiota are associated with many diseases. Consequently, there is growing interest in applying FMT to non-C difficile indications. However, this may succeed only if microbiota therapeutics are developed systematically, based on mechanistic understanding, and applying up-to-date principles of microbial ecology. We discuss 2 pathways in the development of this new therapeutic class: whole microbial communities separated from donor stool and an assembly of specific fecal microorganisms grown in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.